Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2023
PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic CancerLestat R Ali, Patrick J Lenehan, Victoire Cardot-Ruffino, et al.
JAMA Oncology|July 1, 2021
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical TrialOsama E Rahma, Greg Yothers, Theodore S Hong, et al.
Cancer Immunology Research|September 30, 2024
A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal CancerBrandon M Huffman, Osama E Rahma, Kevin Tyan, et al.
Journal of the National Cancer Institute|April 11, 2023
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinomaKristen Spencer, Leontios Pappas, Islam Baiev, et al.
JCO Precision Oncology|August 10, 2023
The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With CholangiocarcinomaLeontios Pappas, Islam Baiev, Stephanie Reyes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2022
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of ResponseTimothy A Yap, Justin F Gainor, Margaret K Callahan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2021
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 MonotherapyXue Bai, Jiani Hu, Allison Betof Warner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal CancerArta M Monjazeb, Anita Giobbie-Hurder, Ana Lako, et al.
Nature Communications|July 9, 2024
Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinomaJacob E Till, Lee McDaniel, Changgee Chang, et al.
Cancer Immunology Research|July 11, 2024
Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the TumorPaul E Oberstein, Andressa Dias Costa, Emily A Kawaler, et al.
Pageof 6